EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

Laurent Mortier, Astrid Blom, Benoît van Hille, Mahtab Samimi, Laura Luciani, Capucine Cahuzac, Caroline Robert, Gaelle Quereux, Eve Maubec, Hakima Miotti, Cathy Maillard, François Aubin und 7 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Laurent Mortier und 18 weiteren Autor:innen. Beteiligte Einrichtung: Lille University, INSERM U 1189, CHU de Lille, CARADERM network, Lille Cedex, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Merkel Cell, Skin Neoplasms, Databases, Factual. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Merkel CellSkin NeoplasmsDatabases, FactualHumansMaleFemaleAgedFranceRetrospective StudiesAged, 80 and overMiddle AgedAntineoplastic Agents, ImmunologicalTreatment OutcomeAdult

Stichwörter der Autor:innen

AvelumabCARADERMImmunotherapyMetastatic Merkel cell carcinomaOverall survivalProgression-free survivalSNDSSecond line

Substanzen

avelumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Lille University, INSERM U 1189, CHU de Lille, CARADERM network, Lille Cedex, France.
  • CHU Ambroise-Paré, Boulogne-Billancourt, France. Electronic address: astrid.blom@aphp.fr.
  • Merck Santé S.A.S. an affiliate of Merck KGaA, Lyon, France.
  • CHU de Tours, Hôpital Trousseau, Tours, France.
  • Gustave Roussy et Université Paris-Saclay Villejuif, France.
  • CHU de Nantes, Hôpital Hôtel-Dieu, Nantes, France.

Förderung

  • Merck KGaA

Zitieren

APA

Mortier, L., Blom, A., van Hille, B., Samimi, M., Luciani, L., Cahuzac, C., Robert, C., Quereux, G., Maubec, E., Miotti, H., Maillard, C., Aubin, F., Lenormand, C., Solbes, M. N., Joly, P., Kachaner, I., Lebbé, C., Dutriaux, C., & Saiag, P. (2024). Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114261

Vancouver

Mortier L, Blom A, van Hille B, Samimi M, Luciani L, Cahuzac C, et al. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114261

BibTeX
@article{Mortier2024,
  author = {Mortier, Laurent and Blom, Astrid and van Hille, Benoît and Samimi, Mahtab and Luciani, Laura and Cahuzac, Capucine and Robert, Caroline and Quereux, Gaelle and Maubec, Eve and Miotti, Hakima and Maillard, Cathy and Aubin, François and Lenormand, Cédric and Solbes, Marie-Noëlle and Joly, Pascal and Kachaner, Isabelle and Lebbé, Céleste and Dutriaux, Caroline and Saiag, Philippe},
  title = {Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114261}
}
Kostenlos starten →